Pay in 4 interest-free payments of $6.13 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Tirzepatide, a Dual GIP/GLP-1 Receptor Co-Agonist for the Treatment of Type 2 Diabetes With Unmatched Effectiveness Regarding Glycaemic Control and Body Weight Reduction
Type 2 diabetes affects over 500 million people worldwide, and obesity affects more than 890 million
This represents an improvement over the ~15% weight loss seen over a similar time period in Wegovy clinical trials, though cross trial comparisons are unreliable
Disclaimer: Always consult your healthcare provider before starting or changing a medication or lab-testing plan
Although use of these products is generally considered safe and well-tolerated, further research is needed to assess any long-term effects
